Ironwood Pharmaceuticals, Inc
Ironwood Pharmaceuticals is a U.S.-based biopharmaceutical company focused on gastrointestinal therapies. Its core business is the commercialization of LINZESS in the U.S. through a collaboration with AbbVie, while it also develops apraglutide for short bowel syndrome and evaluates additional GI opportunities.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueRevenue tied to LINZESS commercialization in the U.S. through a collaboration with AbbVie.
Clinical development of apraglutide and other GI product candidates.
License fees, milestones, and royalties from linaclotide partnerships outside the U.S.
Products
Reported · share of revenue- Collaborative Arrangements99.8 %
- Collaborative Arrangement Other Agreements0.2 %
Source: 10-K FY2024, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Ironwood sells primarily through a partner-led pharmaceutical model rather than direct end-customer sales. Its economic customers are patients and prescribers in gastrointestinal care, while revenue is driven by AbbVie’s commercialization of LINZESS and by partners that pay royalties, milestones, or license fees.
AbbVie commercializes LINZESS in the U.S. and shares net profits/losses with Ironwood.
Patients and physicians using LINZESS for GI indications drive underlying product demand.
Partners in Europe, Canada, Mexico, Japan, China and other markets pay royalties and fees on linaclotide.
Regulators, investigators, and CDMOs support apraglutide development and approval efforts.
Strategy
Ironwood is concentrating on GI therapeutics, using LINZESS cash flows to support pipeline development and selective external innovation. Management is also exploring strategic alternatives while advancing apraglutide and other GI opportunities, reflecting a push to improve long-term growth and shareholder value.
LINZESS remains the main revenue engine, so pricing, reimbursement, and partner execution are critical.
Apraglutide is the main pipeline asset and could diversify revenue beyond LINZESS if approved.
Management is assessing options to maximize shareholder value amid pipeline and market uncertainty.
Geography
Ironwood is headquartered in the United States but now also has operations in Switzerland following the VectivBio acquisition. Its revenue base is still centered on the U.S. through LINZESS, while future upside and risk are tied to regulatory and commercial activity in Europe and other international markets.
Risks
Ironwood is highly exposed to dependence on LINZESS and on AbbVie’s commercialization performance, so pricing pressure or channel fluctuations can quickly affect revenue. Pipeline risk is also elevated because apraglutide still needs additional clinical work and regulatory approval, while foreign operations and pharmaceutical regulation add compliance, currency, and execution risk.
- Apraglutide clinical and regulatory uncertaintyImpact: HighLikelihood: High
FDA indicated a confirmatory Phase III trial is needed before NDA approval.
Exposure: Pipeline development
- Dependence on LINZESS and AbbVie collaborationImpact: HighLikelihood: Medium
Most revenue comes from U.S. LINZESS economics and settlement payments with AbbVie.
Exposure: U.S. commercial performance and partner execution
- Drug pricing and reimbursement reformImpact: HighLikelihood: Medium
Government action on pricing could lower realized net prices and profitability.
Exposure: U.S. and OECD pricing policy
- Manufacturing and supply chain reliance on third partiesImpact: HighLikelihood: Medium
Ironwood has no internal manufacturing or distribution capabilities.
Exposure - Foreign jurisdiction operating riskImpact: MediumLikelihood: Low
Switzerland and other non-U.S. activities create currency, legal, and compliance exposure.
Exposure: Basel and international operations
Accounting
Judgemental itemsRevenue depends on identifying performance obligations and timing of milestone/license recognition.
Impact: Can shift revenue between periods and affect comparability
Management estimates governmental and contractual rebates and allowances.
Impact: Can materially change collaboration revenue and net sales
Reported revenue reflects net profits/losses after commercial expenses and partner settlements.
Impact: Quarterly volatility in revenue and operating margin
Convertible notes and revolving credit facility create interest expense and non-cash amortization.
Impact: Affects net income and cash flow presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Arrowhead Pharmaceuticals, Inc
ARWR · Pharmaceutical Preparations
Arrowhead Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing RNA interference medicines that silence disease-causing genes.
Oramed Pharmaceuticals Inc
ORMP · Pharmaceutical Preparations
Dogwood Therapeutics, Inc.
DWTX · Pharmaceutical Preparations
BioVie Inc
BIVIW · Pharmaceutical Preparations
Gilead Sciences, Inc
GILD · Biological Products, (No Diagnostic Substances)
Gilead Sciences is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases.
Ardelyx, Inc
ARDX · Pharmaceutical Preparations
Last updated: 24/09/2026